Emory University Lung Cancer SPORE

埃默里大学肺癌孢子

基本信息

批准号：
9975749
负责人：
HAIAN FU
金额：
$ 186.51万
依托单位：
EMORY UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-07-10 至 2024-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9975749
关键词：
ABCG2 gene Address Animal Cancer Model Animal Model Area Award Biological Markers Biometry CD8-Positive T-Lymphocytes Cancer Etiology Cancer Patient Cell Fate Control Cessation of life Collaborations Comprehensive Cancer Center Coupled Data Dependence Deuterium Development Diagnosis Disease Drug resistance Epidermal Growth Factor Receptor Funding Goals Health Sciences Healthcare Systems Hematology Human Immune checkpoint inhibitor Immunologic Factors Immunologist Immunotherapy In Vitro Institutes Investigation Ionizing radiation Journals KRAS2 gene Label Location MERTK gene Malignant Neoplasms Malignant neoplasm of lung Mediator of activation protein Medical Oncology Modernization Molecular Molecular Target Mutate Mutation Neoadjuvant Therapy Non-Small-Cell Lung Carcinoma Oncologist Outcome PD-1 blockade Pathology Patient-Focused Outcomes Patients Phenotype Phosphorylation Site Play Prognostic Marker Property Publishing Radiation therapy Recommendation Research Research Personnel Resistance Resource Sharing Role SDZ RAD Safety Scientist Signal Transduction Site T-Lymphocyte TP53 gene Technology Testing Therapeutic Agents Therapy trial Treatment Efficacy Tumor Immunity Universities Work anti-PD1 therapy anti-cancer anticancer research antitumor effect biomedical informatics cancer cell cancer therapy career clinical application clinical efficacy clinical investigation drug discovery experience improved improved outcome in vivo inhibitor/antagonist innovation mTOR inhibition medical schools member molecular targeted therapies mortality multidisciplinary mutant novel novel strategies novel therapeutic intervention patient population phase 1 study preclinical development programmed cell death protein 1 programs radiation resistance resistance mechanism small molecule stem stem-like cell targeted agent targeted treatment therapeutic target therapy resistant translational scientist tumor tumorigenesis

项目摘要

OVERVIEW SUMMARY/ABSTRACT Lung cancer is the leading cause of cancer-related deaths, with more than 1.6 million deaths/year globally. It is often diagnosed at an advanced stage and is associated with poor outcomes for the majority of patients. This application for a lung cancer SPORE award from Emory University brings together an outstanding and multi- disciplinary team of oncologists, immunologists, drug discovery experts, and translational researchers dedicated to lung cancer research to address critical questions that will improve the outcome for patients with this lethal disease. Our proposed program will have significant impact in two crucial areas of lung cancer management: enhancing the efficacy of immunotherapy and overcoming treatment resistance through the development of novel molecularly targeted agents. Through strong teamwork carried out by this highly collaborative team of dedicated investigators, and building on exciting data published in leading journals by our group since our previous SPORE application, this revised submission aims to achieve substantial improvements in the management of patients with non-small cell lung cancer (NSCLC), through three overall Specific Aims: Aim 1: To evaluate stem-like T cells and improve efficacy of checkpoint inhibitors in NSCLC (Project 1); Aim 2: To target MERTK to improve outcomes for EGFR-mutated NSCLC (Project 2); and Aim 3: To target Bax signaling to overcome treatment resistance in NSCLC (Project 3). The Emory Lung Cancer SPORE program will be supported by close interaction with the Administrative Core (Core 1), Pathology Core (Core 2) and the Biostatistics and Biomedical Informatics Core (Core 3), and will conduct Career Enhancement and Developmental Research Programs (CEP and DRP). The SPORE program will benefit from regular advice and recommendations from External and Internal Advisory Board members regarding its progress and direction. Our program will receive strong institutional support including modern research space, excellent shared resources, and a significant level of matching funds (totaling $2.25M) from the Winship Cancer Institute of Emory University (an NCI-designated Comprehensive Cancer Center), Emory University Woodruff Health Sciences Center, Emory Healthcare System, Emory School of Medicine, and the Department of Hematology and Medical Oncology. Through team-driven innovative research efforts in immunotherapies and molecularly targeted therapeutics, we are confident that this SPORE program, in collaboration with other lung cancer SPORE sites, will have a major positive impact on the management of lung cancer.

概述摘要/摘要肺癌是癌症相关死亡的主要原因，全球每年有超过 160 万人死亡。这是通常在晚期才被诊断出来，并且大多数患者的预后不佳。这埃默里大学肺癌 SPORE 奖的申请汇集了杰出的多学科专家由肿瘤学家、免疫学家、药物发现专家和转化研究人员组成的学科团队致力于参与肺癌研究，解决关键问题，从而改善患有这种致命疾病的患者的治疗结果疾病。我们提出的计划将对肺癌管理的两个关键领域产生重大影响：通过开发增强免疫疗法的功效并克服治疗耐药性新型分子靶向药物。通过这个高度协作的团队的强大团队合作专门的研究人员，并以我们小组自成立以来在领先期刊上发表的令人兴奋的数据为基础与之前的 SPORE 应用程序相比，本次修订提交的目的是在通过三个总体具体目标管理非小细胞肺癌 (NSCLC) 患者：目标 1：评估干细胞样T细胞并提高非小细胞肺癌检查点抑制剂的疗效（项目1）；目标 2：以 MERTK 为靶点，改善 EGFR 突变 NSCLC 的预后（项目 2）；目标 3：瞄准 Bax 克服 NSCLC 治疗耐药性的信号（项目 3）。埃默里肺癌 SPORE 计划将通过与行政核心（核心 1）、病理学核心（核心 2）和生物统计学和生物医学信息学核心（核心3），并将进行职业提升和发展研究计划（CEP 和 DRP）。 SPORE 计划将受益于定期的建议和外部和内部顾问委员会成员关于其进展和方向的建议。我们的项目将获得强有力的机构支持，包括现代化的研究空间、优秀的共享资源、以及埃默里大学 Winship 癌症研究所提供的大量配套资金（总计 225 万美元）（NCI 指定的综合癌症中心），埃默里大学伍德拉夫健康科学中心，埃默里医疗保健系统、埃默里医学院以及血液学和肿瘤内科。通过团队驱动的免疫疗法和分子靶向疗法的创新研究工作，我们我们相信，这个 SPORE 计划与其他肺癌 SPORE 站点合作，将产生重大影响对肺癌的治疗产生积极影响。